DSS Inc
DSS0.910USD
+0.050+5.81%
Cierre 06/25, 16:00（ET）Cotizaciones retrasadas 15 min
8.27MCap. mercado
PérdidaP/E TTM
Más Datos de DSS Inc Compañía
DSS, Inc. is a multinational, public company. The Company operates its business through five divisions: Product Packaging, Biotechnology, Commercial Lending, Securities and Investment Management, and Direct Marketing. The Product Packaging division operates through Premier Packaging Corporation, Inc., which markets, manufactures, and sells sophisticated custom folding cartons, mailers, photo sleeves and complex three-dimensional direct mail solutions. Biotechnology division targets unmet, urgent medical needs and expands the borders of medical and pharmaceutical science. Commercial Lending through its operating company, American Pacific Bancorp, Inc., which represents its banking and financing business line. The Direct Marketing is specialized in marketing and distributing its products and services through its subsidiary and partner network, using the gig economic marketing strategy as a form of direct marketing.
Información de la empresa
Símbolo de cotizaciónDSS
Nombre de la empresaDSS Inc
Fecha de salida a bolsaOct 27, 1993
Fundada en1984
Director ejecutivoMr. Jason Grady
Número de empleados100
Tipo de seguridadOrdinary Share
Fin del año fiscalOct 27
Dirección275 Wiregrass Pkwy
CiudadWEST HENRIETTA
Bolsa de valoresNYSE American Consolidated
PaísUnited States of America
Código postal14586
Teléfono15852321500
Sitio Webhttps://www.dssworld.com/
Símbolo de cotizaciónDSS
Fecha de salida a bolsaOct 27, 1993
Fundada en1984
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Jason Grady
Mr. Jason Grady
Interim Chief Executive Officer
Interim Chief Executive Officer
125.00
--
Mr. Jose Escudero
Mr. Jose Escudero
Independent Director
Independent Director
51.00
--
Ms. Hiu Pan (Joanne) Wong
Ms. Hiu Pan (Joanne) Wong
Independent Director
Independent Director
--
--
Mr. Sheng Hon (Danny) Lim
Mr. Sheng Hon (Danny) Lim
Director
Director
--
--
Mr. Heng Fai (Ambrose) Chan
Mr. Heng Fai (Ambrose) Chan
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Mr. Wai Leung (William) Wu
Mr. Wai Leung (William) Wu
Lead Independent Director
Lead Independent Director
--
--
Mr. Todd D. Macko
Mr. Todd D. Macko
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Tung Moe Chan
Mr. Tung Moe Chan
Director
Director
--
--
Mr. Shui Yeung (Frankie) Wong, CPA
Mr. Shui Yeung (Frankie) Wong, CPA
Independent Director
Independent Director
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Jason Grady
Mr. Jason Grady
Interim Chief Executive Officer
Interim Chief Executive Officer
125.00
--
Mr. Jose Escudero
Mr. Jose Escudero
Independent Director
Independent Director
51.00
--
Ms. Hiu Pan (Joanne) Wong
Ms. Hiu Pan (Joanne) Wong
Independent Director
Independent Director
--
--
Mr. Sheng Hon (Danny) Lim
Mr. Sheng Hon (Danny) Lim
Director
Director
--
--
Mr. Heng Fai (Ambrose) Chan
Mr. Heng Fai (Ambrose) Chan
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Mr. Wai Leung (William) Wu
Mr. Wai Leung (William) Wu
Lead Independent Director
Lead Independent Director
--
--
Desglose de ingresos
Divisa: USDActualizado: dom., 6 de abr
Divisa: USDActualizado: dom., 6 de abr
FY2023
FY2023Q1
FY2022
FY2022Q1
FY2021
FY2020
FY2019
Sin datos
Por regiónUSD
Nombre
Ganancia
Proporción
United States
24.12M
93.00%
International
1.82M
7.00%
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: vie., 16 de may
Actualizado: vie., 16 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Alset Ehome International Inc
40.14%
Chan (Heng Fai Ambrose)
13.06%
Global Biomedical Pte Ltd.
3.43%
Heuszel (Frank D.)
0.72%
Citadel Advisors LLC
0.64%
Other
42.01%
Accionistas
Accionistas
Proporción
Alset Ehome International Inc
40.14%
Chan (Heng Fai Ambrose)
13.06%
Global Biomedical Pte Ltd.
3.43%
Heuszel (Frank D.)
0.72%
Citadel Advisors LLC
0.64%
Other
42.01%
Tipos de accionistas
Accionistas
Proporción
Corporation
43.57%
Individual Investor
13.78%
Hedge Fund
0.98%
Investment Advisor/Hedge Fund
0.46%
Investment Advisor
0.37%
Other
40.84%
Participación institucional
Actualizado: lun., 3 de mar
Actualizado: lun., 3 de mar
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q1
42
5.34M
58.69%
-78.37K
2024Q4
44
5.34M
75.51%
+934.13K
2024Q3
50
4.36M
61.72%
-49.38K
2024Q2
55
4.37M
61.87%
-23.78K
2024Q1
58
4.35M
61.59%
-43.12K
2023Q4
57
4.38M
62.50%
-18.04K
2023Q3
61
4.33M
61.80%
-325.98K
2023Q2
66
4.33M
62.32%
-279.86K
2023Q1
73
4.27M
61.44%
-358.54K
2022Q4
74
4.28M
61.51%
-341.22K
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Alset Ehome International Inc
3.65M
40.14%
--
--
Feb 06, 2025
Chan (Heng Fai Ambrose)
2.19M
24.06%
+1.00M
+84.21%
Feb 06, 2025
Global Biomedical Pte Ltd.
311.63K
3.43%
--
--
Feb 06, 2025
Heuszel (Frank D.)
65.64K
0.72%
--
--
Aug 30, 2024
Renaissance Technologies LLC
25.25K
0.28%
+2.00K
+8.60%
Dec 31, 2024
The Vanguard Group, Inc.
43.32K
0.48%
-36.99K
-46.06%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
20.98K
0.23%
--
--
Dec 31, 2024
Geode Capital Management, L.L.C.
12.51K
0.14%
--
--
Dec 31, 2024
Ferguson Wellman Capital Management, Inc.
12.75K
0.14%
-12.75K
-50.00%
Dec 31, 2024
Ver más
ETFs relacionados
Actualizado: vie., 6 de jun
Actualizado: vie., 6 de jun
Nombre
Proporción
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Nov 08, 2023
Merger
20<1
Nov 08, 2023
Merger
20<1
Nov 08, 2023
Merger
20<1
Nov 08, 2023
Merger
20<1
May 05, 2020
Merger
30<1
May 05, 2020
Merger
30<1
Fecha
Tipo
Relación
Nov 08, 2023
Merger
20<1
Nov 08, 2023
Merger
20<1
Nov 08, 2023
Merger
20<1
Nov 08, 2023
Merger
20<1
May 05, 2020
Merger
30<1
May 05, 2020
Merger
30<1
May 05, 2020
Merger
30<1
May 05, 2020
Merger
30<1
